{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:08:57Z","timestamp":1783987737024,"version":"3.55.0"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-026-01223-4","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:35:26Z","timestamp":1779276926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting tumor-associated G-protein coupled receptors: beyond single-axis inhibition toward multidimensional regulation"],"prefix":"10.1007","volume":"49","author":[{"given":"Xia","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianbao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0564-0415","authenticated-orcid":false,"given":"Liuying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0449-236X","authenticated-orcid":false,"given":"Shilin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1625-8682","authenticated-orcid":false,"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"1","key":"1223_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12943-024-02064-1","volume":"23","author":"X. Chu","year":"2024","unstructured":"X. Chu, Y. Tian, C. Lv, Decoding the spatiotemporal heterogeneity of tumor-associated macrophages. Mol. Cancer 23(1), 150 (2024). https:\/\/doi.org\/10.1186\/s12943-024-02064-1","journal-title":"Mol Cancer"},{"issue":"1","key":"1223_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12943-025-02357-z","volume":"24","author":"H. Sabit","year":"2025","unstructured":"H. Sabit, T.M. Pawlik, F. Radwan, M. Abdel-Hakeem, S. Abdel-Ghany, A.-H.S. Wadan, M. Elzawahri, A. El-Hashash, B. Arneth, Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery. Mol. Cancer 24(1), 160 (2025). https:\/\/doi.org\/10.1186\/s12943-025-02357-z","journal-title":"Mol Cancer"},{"issue":"1","key":"1223_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","volume":"12","author":"Z.-F. Lim","year":"2019","unstructured":"Z.-F. Lim, P.C. Ma, Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J. Hematol. Oncol. 12(1), 134 (2019). https:\/\/doi.org\/10.1186\/s13045-019-0818-2","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"1223_CR4","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.trecan.2025.04.016","volume":"11","author":"N. Goto","year":"2025","unstructured":"N. Goto, J. Agudo, \u00d6.H. Yilmaz, Early immune evasion in colorectal cancer: interplay between stem cells and the tumor microenvironment. Trends Cancer 11(9), 850\u2013861 (2025). https:\/\/doi.org\/10.1016\/j.trecan.2025.04.016","journal-title":"Trends Cancer"},{"issue":"7934","key":"1223_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41586-022-05343-3","volume":"611","author":"Y. Kwon","year":"2022","unstructured":"Y. Kwon, S. Mehta, M. Clark, G. Walters, Y. Zhong, H.N. Lee, R.K. Sunahara, J. Zhang, Non-canonical \u03b2-adrenergic activation of ERK at endosomes. Nature 611(7934), 173\u2013179 (2022). https:\/\/doi.org\/10.1038\/s41586-022-05343-3","journal-title":"Nature"},{"issue":"5","key":"1223_CR6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1124\/pharmrev.121.000302","volume":"75","author":"J. Wess","year":"2023","unstructured":"J. Wess, A.-B. Oteng, O. Rivera-Gonzalez, E.V. Gurevich, V.V. Gurevich, \u03b2\u2212Arrestins: structure, function, physiology, and pharmacological perspectives. Pharmacol. Rev. 75(5), 854\u2013884 (2023). https:\/\/doi.org\/10.1124\/pharmrev.121.000302","journal-title":"Pharmacol. Rev."},{"issue":"12","key":"1223_CR7","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.3390\/cells10123288","volume":"10","author":"P.K. Chaudhary","year":"2021","unstructured":"P.K. Chaudhary, S. Kim, An Insight into GPCR and G-proteins as cancer drivers. Cells 10(12), 3288 (2021). https:\/\/doi.org\/10.3390\/cells10123288","journal-title":"Cells"},{"issue":"3","key":"1223_CR8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/cancers15030736","volume":"15","author":"H. Yan","year":"2023","unstructured":"H. Yan, J.L. Zhang, K.T. Leung, K.-W. Lo, J. Yu, K.-F. To, W. Kang, An update of G-Protein-coupled receptor signaling and its deregulation in gastric carcinogenesis. Cancers (Basel) 15(3), 736 (2023). https:\/\/doi.org\/10.3390\/cancers15030736","journal-title":"Cancers (Basel)"},{"key":"1223_CR9","doi-asserted-by":"publisher","unstructured":"X. Yin, X. Ma, 492P wound stress stimulation promotes lung metastasis of breast cancer by regulating CXCL12\/CXCR4 axis through MDSC exosome miR-126a-5p. Ann. Oncol. 34, S388 (2023). https:\/\/doi.org\/10.1016\/j.annonc.2023.09.668","DOI":"10.1016\/j.annonc.2023.09.668"},{"issue":"3","key":"1223_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1158\/0008-5472.Can-19-1577","volume":"80","author":"Y. Long","year":"2020","unstructured":"Y. Long, H. Tao, A. Karachi, A.J. Grippin, L. Jin, Y. Chang, W. Zhang, K.A. Dyson, A.Y. Hou, M. Na, L.P. Deleyrolle, E.J. Sayour, M. Rahman, D.A. Mitchell, Z. Lin, J. Huang, Dysregulation of glutamate transport enhances treg function that promotes VEGF blockade resistance in glioblastoma. Cancer Res. 80(3), 499\u2013509 (2020). https:\/\/doi.org\/10.1158\/0008-5472.Can-19-1577","journal-title":"Cancer Res."},{"issue":"17","key":"1223_CR11","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1158\/0008-5472.Can-21-1112","volume":"81","author":"F. Yue","year":"2021","unstructured":"F. Yue, W. Jiang, A.T. Ku, A.I.J. Young, W. Zhang, E.P. Souto, Y. Gao, Z. Yu, Y. Wang, C.J. Creighton, C. Nagi, T. Wang, S.G. Hilsenbeck, X.-H. Feng, S. Huang, C. Coarfa, X.H.-F. Zhang, Q. Liu, X. Lin, Y. Li, A Wnt-independent LGR4\u2013EGFR signaling axis in cancer metastasis. Cancer Res. 81(17), 4441\u20134454 (2021). https:\/\/doi.org\/10.1158\/0008-5472.Can-21-1112","journal-title":"Cancer Res."},{"key":"1223_CR12","doi-asserted-by":"publisher","unstructured":"C. Dong, H. Ma, N. Mi, W. Fu, J. Yi, L. Gao, H. Wang, Y. Ren, Y. Lin, F. Han, Z. Chen, W. Zhou, Integrated analysis of scRNA-seq and bulk RNA-seq reveals that GPRC5A is an important prognostic gene in pancreatic cancer and is associated with B-cell infiltration in pancreatic cancer. Original Research. Front. Oncol. 14 (2024). https:\/\/doi.org\/10.3389\/fonc.2024.1283164","DOI":"10.3389\/fonc.2024.1283164"},{"issue":"12","key":"1223_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nrd.2017.178","volume":"16","author":"A.S. Hauser","year":"2017","unstructured":"A.S. Hauser, M.M. Attwood, M. Rask-Andersen, H.B. Schi\u00f6th, D.E. Gloriam, Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug. Discov. 16(12), 829\u2013842 (2017). https:\/\/doi.org\/10.1038\/nrd.2017.178","journal-title":"Nat Rev Drug. Discov."},{"key":"1223_CR14","doi-asserted-by":"publisher","unstructured":"C. Lyu, Y. Ye, M.M. Lensing, K.-U. Wagner, R.J. Weigel, S. Chen, Targeting Gi\/o protein\u2013coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy. JCI Insight 6(18). https:\/\/doi.org\/10.1172\/jci.insight.150532","DOI":"10.1172\/jci.insight.150532"},{"key":"1223_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jare.2025.08.052","volume":"83","author":"E. Varghese","year":"2026","unstructured":"E. Varghese, S.M. Samuel, S. Hornak, P. Kubatka, D. B\u00fcsselberg, Unraveling the nexus in the neuro-neoplastic progression of colorectal cancer: potential role of \u03b22-adrenergic receptor (\u03b22-AR). J. Adv. Res. 83, 1005\u20131019 (2026). https:\/\/doi.org\/10.1016\/j.jare.2025.08.052","journal-title":"J. Adv. Res."},{"issue":"2","key":"1223_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/cmr.0000000000000943","volume":"34","author":"B. Switzer","year":"2024","unstructured":"B. Switzer, I. Puzanov, S. Gandhi, E.A. Repasky, Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates oncogenic immunity. Melanoma Res. 34(2), 89\u201395 (2024). https:\/\/doi.org\/10.1097\/cmr.0000000000000943","journal-title":"Melanoma Res."},{"issue":"11","key":"1223_CR17","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","volume":"31","author":"R. Sun","year":"2023","unstructured":"R. Sun, Y. Sun, C. Wu, Y. Liu, M. Zhou, Y. Dong, G. Du, H. Luo, B. Shi, H. Jiang, Z. Li, CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-\u03baB\/SDF-1\u03b1 axis to enhance efficacy against pancreatic cancer. Mol. Ther. 31(11), 3193\u20133209 (2023). https:\/\/doi.org\/10.1016\/j.ymthe.2023.09.010","journal-title":"Mol. Ther."},{"issue":"1","key":"1223_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/2208176","volume":"2022","author":"X. Tian","year":"2022","unstructured":"X. Tian, J. Wang, L. Jiang, Y. Jiang, J. Xu, X. Feng, Chemokine\/GPCR signaling-mediated EMT in cancer metastasis. J. Oncol. 2022(1), 1\u201315 (2022). https:\/\/doi.org\/10.1155\/2022\/2208176","journal-title":"J. Oncol."},{"issue":"12","key":"1223_CR19","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.tibs.2021.08.006","volume":"46","author":"S.O. Smith","year":"2021","unstructured":"S.O. Smith, Deconstructing the transmembrane core of class a G protein\u2013coupled receptors. Trends Biochem. Sci. 46(12), 1017\u20131029 (2021). https:\/\/doi.org\/10.1016\/j.tibs.2021.08.006","journal-title":"Trends Biochem. Sci."},{"issue":"41","key":"1223_CR20","doi-asserted-by":"publisher","first-page":"12412","DOI":"10.1002\/anie.201707200","volume":"56","author":"F. Hausch","year":"2017","unstructured":"F. Hausch, Cryo-EM structures of class B GPCR reveal the activation mechanism. Angew. Chem. Int. Ed. 56(41), 12412\u201312414 (2017). https:\/\/doi.org\/10.1002\/anie.201707200","journal-title":"Angew Chem Int Ed"},{"issue":"12","key":"1223_CR21","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.tibs.2017.10.003","volume":"42","author":"de Graaf C","year":"2017","unstructured":"de Graaf C., G. Song, C. Cao, C. de Graaf, Q. Zhao, M.-W. Wang, B. Wu, R.C. Stevens, Extending the structural view of class B GPCRs. Trends Biochem. Sci. 42(12), 946\u2013960 (2017). https:\/\/doi.org\/10.1016\/j.tibs.2017.10.003","journal-title":"Trends Biochem. Sci."},{"issue":"8","key":"1223_CR22","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.tibs.2023.05.007","volume":"48","author":"F. Seufert","year":"2023","unstructured":"F. Seufert, Y.K. Chung, P.W. Hildebrand, T. Langenhan, 7TM domain structures of adhesion GPCRs: what\u2019s new and what\u2019s missing? Trends Biochem. Sci. 48(8), 726\u2013739 (2023). https:\/\/doi.org\/10.1016\/j.tibs.2023.05.007","journal-title":"Trends Biochem. Sci."},{"issue":"1","key":"1223_CR23","doi-asserted-by":"publisher","first-page":"8288","DOI":"10.1038\/s41467-023-44013-4","volume":"14","author":"C. Habrian","year":"2023","unstructured":"C. Habrian, N. Latorraca, Z. Fu, E.Y. Isacoff, homo- and hetero-dimeric subunit interactions set affinity and efficacy in metabotropic glutamate receptors. Nat. Commun. 14(1), 8288 (2023). https:\/\/doi.org\/10.1038\/s41467-023-44013-4","journal-title":"Nat Commun."},{"issue":"10","key":"1223_CR24","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41594-022-00838-z","volume":"29","author":"J.T. Happ","year":"2022","unstructured":"J.T. Happ, C.D. Arveseth, J. Bruystens, D. Bertinetti, I.B. Nelson, C. Olivieri, J. Zhang, D.S. Hedeen, J.-F. Zhu, J.L. Capener, J.W. Br\u00f6ckel, L. Vu, C.C. King, V.L. Ruiz-Perez, X. Ge, G. Veglia, F.W. Herberg, S.S. Taylor, B.R. Myers, A PKA inhibitor motif within SMOOTHENED controls Hedgehog signal transduction. Nat. Struct. Mol. Biol. 29(10), 990\u2013999 (2022). https:\/\/doi.org\/10.1038\/s41594-022-00838-z","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"1223_CR25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev-pharmtox-040623-115054","volume":"64","author":"M.J. Lohse","year":"2024","unstructured":"M.J. Lohse, A. Bock, M. Zaccolo, G protein\u2013coupled receptor signaling: new insights define cellular nanodomains. Annu. Rev. Pharmacol. Toxicol. 64(1), 387\u2013415 (2024). https:\/\/doi.org\/10.1146\/annurev-pharmtox-040623-115054","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"6480","key":"1223_CR26","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1126\/science.aaz0326","volume":"367","author":"C.-M. Suomivuori","year":"2020","unstructured":"C.-M. Suomivuori, N.R. Latorraca, L.M. Wingler, S. Eismann, M.C. King, A.L.W. Kleinhenz, M.A. Skiba, D.P. Staus, A.C. Kruse, R.J. Lefkowitz, R.O. Dror, Molecular mechanism of biased signaling in a prototypical G protein\u2013coupled receptor. Science 367(6480), 881\u2013887 (2020). https:\/\/doi.org\/10.1126\/science.aaz0326","journal-title":"Science"},{"issue":"6480","key":"1223_CR27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1126\/science.aay9813","volume":"367","author":"L.M. Wingler","year":"2020","unstructured":"L.M. Wingler, M.A. Skiba, C. McMahon, D.P. Staus, A.L.W. Kleinhenz, C.-M. Suomivuori, N.R. Latorraca, R.O. Dror, R.J. Lefkowitz, A.C. Kruse, Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR. Science 367(6480), 888\u2013892 (2020). https:\/\/doi.org\/10.1126\/science.aay9813","journal-title":"Science"},{"key":"1223_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.pharmthera.2018.11.008","volume":"196","author":"P. Huang","year":"2019","unstructured":"P. Huang, R. Yan, X. Zhang, L. Wang, X. Ke, Y. Qu, Activating Wnt\/\u03b2-catenin signaling pathway for disease therapy: challenges and opportunities. Pharmacol. Ther. 196, 79\u201390 (2019). https:\/\/doi.org\/10.1016\/j.pharmthera.2018.11.008","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"1223_CR29","doi-asserted-by":"publisher","first-page":"7644","DOI":"10.1038\/s41467-024-52174-z","volume":"15","author":"Y. Qian","year":"2024","unstructured":"Y. Qian, Z. Ma, Z. Xu, Y. Duan, Y. Xiong, R. Xia, X. Zhu, Z. Zhang, X. Tian, H. Yin, J. Liu, J. Song, Y. Lu, A. Zhang, C. Guo, L. Jin, W.J. Kim, J. Ke, F. Xu, Z. Huang, Y. He, Structural basis of frizzled 4 in recognition of Dishevelled 2 unveils mechanism of WNT signaling activation. Nat. Commun. 15(1), 7644 (2024). https:\/\/doi.org\/10.1038\/s41467-024-52174-z","journal-title":"Nat Commun."},{"issue":"6","key":"1223_CR30","doi-asserted-by":"publisher","first-page":"101369","DOI":"10.1016\/j.jbc.2021.101369","volume":"297","author":"Y. Zang","year":"2021","unstructured":"Y. Zang, A.W. Kahsai, N. Pakharukova, L.-Y. Huang, R.J. Lefkowitz, The GPCR\u2013\u03b2-arrestin complex allosterically activates C-Raf by binding its amino terminus. J. Biol. Chem. 297(6), 101369 (2021). https:\/\/doi.org\/10.1016\/j.jbc.2021.101369","journal-title":"J. Biol. Chem."},{"key":"1223_CR31","doi-asserted-by":"publisher","unstructured":"A.W. Kahsai, K.S. Shah, P.J. Shim, M.A. Lee, B.N. Shreiber, A.M. Schwalb, X. Zhang, H.Y. Kwon, L.-Y. Huang, E.J. Soderblom, S. Ahn, R.J. Lefkowitz, Signal transduction at GPCRs: allosteric activation of the ERK MAPK by \u03b2-arrestin. Proc. Natl.Acad. Sci. U. S. A. 120(43), e2303794120 (2023). https:\/\/doi.org\/10.1073\/pnas.2303794120","DOI":"10.1073\/pnas.2303794120"},{"key":"1223_CR32","doi-asserted-by":"publisher","unstructured":"C. Qu, J.Y. Park, M.W. Yun, Q.-T. He, F. Yang, K. Kim, D. Ham, R.-R. Li, T.M. Iverson, V.V. Gurevich, J.-P. Sun, K.Y. Chung, Scaffolding mechanism of arrestin-2 in the cRaf\/MEK1\/ERK signaling cascade. Proc. Natl. Acad. Sci. U. S. A. 118(37), e2026491118 (2021). https:\/\/doi.org\/10.1073\/pnas.2026491118","DOI":"10.1073\/pnas.2026491118"},{"issue":"2","key":"1223_CR33","doi-asserted-by":"publisher","first-page":"189266","DOI":"10.1016\/j.bbcan.2025.189266","volume":"1880","author":"L. Li","year":"2025","unstructured":"L. Li, Z. An, C. Lin, Q. Xu, C. Tang, An update on regulation and function of G protein-coupled receptors in cancer: a promising strategy for cancer therapy. Biochim. Et Biophys. Acta (BBA) - Rev. Cancer 1880(2), 189266 (2025). https:\/\/doi.org\/10.1016\/j.bbcan.2025.189266","journal-title":"Biochim. Et Biophys. Acta (BBA) - Rev. Cancer"},{"key":"1223_CR34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.semcancer.2022.02.017","volume":"86","author":"M. Mughees","year":"2022","unstructured":"M. Mughees, J.B. Kaushal, G. Sharma, S. Wajid, S.K. Batra, J.A. Siddiqui, Chemokines and cytokines: axis and allies in prostate cancer pathogenesis. Semin. Cancer Biol. 86, 497\u2013512 (2022). https:\/\/doi.org\/10.1016\/j.semcancer.2022.02.017.","journal-title":"Semin. Cancer Biol."},{"key":"1223_CR35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.semcancer.2022.11.005","volume":"87","author":"P. Khan","year":"2022","unstructured":"P. Khan, M. Fatima, M.A. Khan, S.K. Batra, M.W. Nasser, Emerging role of chemokines in small cell lung cancer: road signs for metastasis, heterogeneity, and immune response. Semin. Cancer Biol. 87, 117\u2013126 (2022). https:\/\/doi.org\/10.1016\/j.semcancer.2022.11.005.","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"1223_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41568-021-00427-0","volume":"22","author":"F. Weiss","year":"2022","unstructured":"F. Weiss, D. Lauffenburger, P. Friedl, Towards targeting of shared mechanisms of cancer metastasis and therapy resistance. Nat. Rev. Cancer 22(3), 157\u2013173 (2022). https:\/\/doi.org\/10.1038\/s41568-021-00427-0","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"1223_CR37","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1158\/1078-0432.Ccr-18-3557","volume":"25","author":"J. Zhang","year":"2019","unstructured":"J. Zhang, J. Chen, D. Wo, H. Yan, P. Liu, E. Ma, L. Li, L. Zheng, D. Chen, Z. Yu, C. Liang, J. Peng, D.-N. Ren, W. Zhu, LRP6 ectodomain prevents SDF-1\/CXCR4-induced breast cancer metastasis to lung. Clin. Cancer Res. 25(15), 4832\u20134845 (2019). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3557","journal-title":"Clin. Cancer Res."},{"key":"1223_CR38","doi-asserted-by":"publisher","first-page":"216870","DOI":"10.1016\/j.canlet.2024.216870","volume":"590","author":"Y. Xin","year":"2024","unstructured":"Y. Xin, B. Hu, K. Li, G. Hu, C. Zhang, X. Chen, K. Tang, P. Du, Y. Tan, Circulating tumor cells with metastasis-initiating competence survive fluid shear stress during hematogenous dissemination through CXCR4-PI3K\/AKT signaling. Cancer Lett. 590, 216870 (2024). https:\/\/doi.org\/10.1016\/j.canlet.2024.216870","journal-title":"Cancer Lett."},{"issue":"4","key":"1223_CR39","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1161\/ATVBAHA.107.160044","volume":"28","author":"F. Zemani","year":"2008","unstructured":"F. Zemani, J.-S. Silvestre, F. Fauvel-Lafeve, A. Bruel, J. Vilar, I. Bieche, I. Laurendeau, I. Galy-Fauroux, A.M. Fischer, C. Boisson-Vidal, Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler. Thromb. Vasc. Biol. 28(4), 644\u2013650 (2008). https:\/\/doi.org\/10.1161\/ATVBAHA.107.160044","journal-title":"ATVB"},{"issue":"1","key":"1223_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-023-01789-9","volume":"22","author":"J. Yang","year":"2023","unstructured":"J. Yang, K. Bergdorf, C. Yan, W. Luo, S.C. Chen, G.D. Ayers, Q. Liu, X. Liu, M. Boothby, V.L. Weiss, S.M. Groves, A.N. Oleskie, X. Zhang, D.Y. Maeda, J.A. Zebala, V. Quaranta, A. Richmond, CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth. Mol. Cancer 22(1), 92 (2023). https:\/\/doi.org\/10.1186\/s12943-023-01789-9","journal-title":"Mol Cancer"},{"issue":"1","key":"1223_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13058-019-1243-8","volume":"22","author":"L.J. Goldstein","year":"2020","unstructured":"L.J. Goldstein, R.P. Perez, D. Yardley, L.K. Han, J.M. Reuben, H. Gao, S. McCanna, B. Butler, P.A. Ruffini, Y. Liu, R.R. Rosato, J.C. Chang, A window-of-opportunity trial of the CXCR1\/2 inhibitor reparixin in operable HER-2-negative breast cancer. Emerg. Cancer Ther. Res. 22(1), 4 (2020). https:\/\/doi.org\/10.1186\/s13058-019-1243-8","journal-title":"Emerg. Cancer Ther. Res."},{"issue":"19","key":"1223_CR42","doi-asserted-by":"publisher","first-page":"11757","DOI":"10.3390\/ijms231911757","volume":"23","author":"N. Babst","year":"2022","unstructured":"N. Babst, L.K. Isbell, F. Rommel, A. Tura, M. Ranjbar, S. Grisanti, C. Tschuch, J. Schueler, S. Doostkam, P.C. Reinacher, J. Duyster, V. Kakkassery, N. von Bubnoff, CXCR4, CXCR5 and CD44 may be involved in homing of lymphoma cells into the eye in a patient derived xenograft homing mouse model for primary vitreoretinal lymphoma. Int. J. Mol. Sci. 23(19), 11757 (2022). https:\/\/doi.org\/10.3390\/ijms231911757","journal-title":"Int J Mol Sci."},{"issue":"1","key":"1223_CR43","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12931-020-01518-6","volume":"21","author":"H. Liu","year":"2020","unstructured":"H. Liu, Q. Cheng, D.-S. Xu, W. Wang, Z. Fang, D.-D. Xue, Y. Zheng, A.H. Chang, Y.-J. Lei, Overexpression of CXCR7 accelerates tumor growth and metastasis of lung cancer cells. Respir Res. 21(1), 287 (2020). https:\/\/doi.org\/10.1186\/s12931-020-01518-6","journal-title":"Respir Res."},{"issue":"13","key":"1223_CR44","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.7150\/ijbs.74647","volume":"18","author":"W. Xu","year":"2022","unstructured":"W. Xu, Y. Wu, W. Liu, A. Anwaier, X. Tian, J. Su, H. Huang, G. Wei, Y. Qu, H. Zhang, D. Ye, Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma. Int. J. Biol. Sci. 18(13), 4884\u20134900 (2022). https:\/\/doi.org\/10.7150\/ijbs.74647","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"1223_CR45","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jhep.2021.08.029","volume":"76","author":"Y. Gao","year":"2022","unstructured":"Y. Gao, M. You, J. Fu, M. Tian, X. Zhong, C. Du, Z. Hong, Z. Zhu, J. Liu, G.J. Markowitz, F.-S. Wang, P. Yang, Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B. J. Educ. Chang. Hepatol. 76(1), 148\u2013159 (2022). https:\/\/doi.org\/10.1016\/j.jhep.2021.08.029","journal-title":"J. Educ. Chang. Hepatol."},{"key":"1223_CR46","doi-asserted-by":"publisher","unstructured":"J. Wang, Q. Tao, K. Huang, Y. Wang, L. Hu, A. Ren, H. Wang, Y. Wan, J. Li, L. Yi, Y. Ruan, Z. Wanyan, F. Wu, Z. Zhai, C. Liu, Chemotherapy-induced cellular senescence promotes stemness of aggressive B-cell non-Hodgkin\u2019s lymphoma via CCR7\/ARHGAP18\/IKB\u03b1 signaling activation. J. Immunother. Cancer. 13(1), e009356 (2025). https:\/\/doi.org\/10.1136\/jitc-2024-009356","DOI":"10.1136\/jitc-2024-009356"},{"key":"1223_CR47","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.actbio.2025.03.049","volume":"197","author":"Y. Liu","year":"2025","unstructured":"Y. Liu, X. Chen, W. Zhang, B. Yu, Y. Cen, Q. Liu, Y. Tang, S. Li, A CXCR4-targeted immunomodulatory nanomedicine for photodynamic amplified immune checkpoint blockade therapy against breast cancer. Acta Biomaterialia 197, 400\u2013415 (2025). https:\/\/doi.org\/10.1016\/j.actbio.2025.03.049","journal-title":"Acta Biomaterialia"},{"issue":"1","key":"1223_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13058-021-01391-1","volume":"23","author":"X. Jiao","year":"2021","unstructured":"X. Jiao, M. Wang, Z. Zhang, Z. Li, D. Ni, A.W. Ashton, H.-Y. Tang, D.W. Speicher, R.G. Pestell, Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. Breast Cancer Res. 23(1), 11 (2021). https:\/\/doi.org\/10.1186\/s13058-021-01391-1","journal-title":"Emerg. Cancer Ther. Res."},{"issue":"21","key":"1223_CR49","doi-asserted-by":"publisher","first-page":"15965","DOI":"10.3390\/ijms242115965","volume":"24","author":"P. Fanis","year":"2023","unstructured":"P. Fanis, V. Neocleous, I. Papapetrou, L.A. Phylactou, N. Skordis, Gonadotropin-releasing hormone receptor (GnRHR) and hypogonadotropic hypogonadism. Int. J. Mol. Sci. 24(21), 15965 (2023). https:\/\/doi.org\/10.3390\/ijms242115965","journal-title":"Int J Mol Sci."},{"issue":"10","key":"1223_CR50","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1093\/jnci\/djae115","volume":"116","author":"J. Lin","year":"2024","unstructured":"J. Lin, Y. Ouyang, Y. Li, L. Jin, S. Li, Y. Liu, Y. Yang, Q. Shi, M. Zhu, Z. Cai, J. Wang, N. Liu, Y. Hu, Z. Wu, M. Wu, L.L. Wong, X. Jiang, Q. Wang, W. Yang, Q. Liu, Different dosage forms of gonadotropin-releasing hormone agonist with endocrine therapy in premenopausal hormone receptor\u2013positive breast cancer. JNCI J. Natl. Cancer. Inst. 116(10), 1587\u20131597 (2024). https:\/\/doi.org\/10.1093\/jnci\/djae115","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"16","key":"1223_CR51","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R. Raychaudhuri","year":"2025","unstructured":"R. Raychaudhuri, D.W. Lin, R.B. Montgomery, Prostate cancer: a review. JAMA 333(16), 1433\u20131446 (2025). https:\/\/doi.org\/10.1001\/jama.2025.0228","journal-title":"JAMA"},{"issue":"6","key":"1223_CR52","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.eururo.2023.09.007","volume":"84","author":"B. Tombal","year":"2023","unstructured":"B. Tombal, S. Collins, A.K. Morgans, E. Hunsche, B. Brown, E. Zhu, A. Bossi, N. Shore, Impact of Relugolix versus Leuprolide on the quality of life of men with advanced prostate cancer: results from the phase 3 HERO study. Eur. Urol. 84(6), 579\u2013587 (2023). https:\/\/doi.org\/10.1016\/j.eururo.2023.09.007","journal-title":"Eur. Urol."},{"issue":"1","key":"1223_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12916-023-02834-6","volume":"21","author":"X. Li","year":"2023","unstructured":"X. Li, F. Sun, X. Zhang, P. Lin, K. Shen, Y. Shen, L. Ma, Y. Cao, C. Wang, Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study. BMC Med. 21(1), 129 (2023). https:\/\/doi.org\/10.1186\/s12916-023-02834-6","journal-title":"BMC Med."},{"issue":"1","key":"1223_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1210\/endrev\/bnae022","volume":"46","author":"B. Zhang","year":"2025","unstructured":"B. Zhang, L. Xue, Z.B. Wu, Structure and function of somatostatin and its receptors in endocrinology. Endocr. Rev. 46(1), 26\u201342 (2025). https:\/\/doi.org\/10.1210\/endrev\/bnae022","journal-title":"Endocr. Rev."},{"issue":"32","key":"1223_CR55","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/jco.23.01529","volume":"41","author":"J.D. Rivero","year":"2023","unstructured":"J.D. Rivero, K. Perez, E.B. Kennedy, E.S. Mittra, N. Vijayvergia, J. Arshad, S. Basu, A. Chauhan, A.N. Dasari, A.M. Bellizzi, A. Gangi, E. Grady, J.R. Howe, J. Ivanidze, M. Lewis, J. Mailman, N. Raj, H.P. Soares, M.C. Soulen, S.B. White, J.A. Chan, P.L. Kunz, S. Singh, T.R. Halfdanarson, J.R. Strosberg, E.K. Bergsland, Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. J. Retailing Clin. Oncol. 41(32), 5049\u20135067 (2023). https:\/\/doi.org\/10.1200\/jco.23.01529","journal-title":"J. Retailing Clin. Oncol."},{"issue":"4","key":"1223_CR56","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2967\/jnumed.120.249607","volume":"62","author":"C. Mirian","year":"2021","unstructured":"C. Mirian, A.K. Duun-Henriksen, A. Maier, M.M. Pedersen, L.R. Jensen, A. Bashir, T. Graillon, M. Hrachova, D. Bota, M. van Essen, P. Spanjol, C. Kreis, I. Law, H. Broholm, L. Poulsgaard, K. Fugleholm, M. Ziebell, T. Munch, M.A. Walter, T. Mathiesen, Somatostatin receptor\u2013targeted radiopeptide therapy in treatment-refractory Meningioma: individual patient data meta-analysis. J. Nucl. Med. 62(4), 507\u2013513 (2021). https:\/\/doi.org\/10.2967\/jnumed.120.249607","journal-title":"J. Nucl. Med."},{"issue":"9","key":"1223_CR57","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/1535-7163.Mct-22-0798","volume":"22","author":"R. Sharma","year":"2023","unstructured":"R. Sharma, B. Earla, K.E. Baidoo, M.A. Zeiger, J.P. Madigan, F.E. Escorcia, S.M. Sadowski, Upregulation of somatostatin receptor type 2 improves 177Lu-DOTATATE therapy in receptor-deficient pancreatic neuroendocrine tumor model. Mol Cancer Ther. 22(9), 1052\u20131062 (2023). https:\/\/doi.org\/10.1158\/1535-7163.Mct-22-0798","journal-title":"Mol Cancer Ther."},{"issue":"24","key":"1223_CR58","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1200\/jco.22.00176","volume":"40","author":"T.A. Hope","year":"2022","unstructured":"T.A. Hope, M. Pavel, E.K. Bergsland, neuroendocrine tumors and peptide receptor radionuclide therapy: When is the right time? J. Retailing Clin. Oncol. 40(24), 2818\u20132829 (2022). https:\/\/doi.org\/10.1200\/jco.22.00176","journal-title":"J. Retailing Clin. Oncol."},{"key":"1223_CR59","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3389\/fphar.2020.601887","volume":"11","author":"B. K\u00e1nt\u00e1s","year":"2021","unstructured":"B. K\u00e1nt\u00e1s, \u00c9. Sz\u0151ke, R. B\u00f6rzsei, P. B\u00e1nhegyi, J. Asghar, L. Hudhud, A. Steib, \u00c1. Hunyady, \u00c1. Horv\u00e1th, A. Kecsk\u00e9s, \u00c9. Borb\u00e9ly, C. Het\u00e9nyi, G. Peth\u0151, E. Pint\u00e9r, Z. Helyes, In silico, in vitro and in vivo pharmacodynamic characterization of novel analgesic drug candidate somatostatin sst4 receptor agonists. Original Research. Front. Pharmacol. 11, 2020 (2021). https:\/\/doi.org\/10.3389\/fphar.2020.601887","journal-title":"Front Pharmacol."},{"issue":"7954","key":"1223_CR60","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41586-023-05802-5","volume":"615","author":"N. Scholz","year":"2023","unstructured":"N. Scholz, A.-K. Dahse, M. Kemkemer, A. Bormann, G.M. Auger, F. Vieira Contreras, L.F. Ernst, H. Staake, M.B. K\u00f6rner, M. Buhlan, A. Meyer-M\u00f6lck, Y.K. Chung, B. Blanco-Redondo, F. Klose, M.A. Jarboui, D. Ljaschenko, M. Bigl, T. Langenhan, Molecular sensing of mechano- and ligand-dependent adhesion GPCR dissociation. Nature 615(7954), 945\u2013953 (2023). https:\/\/doi.org\/10.1038\/s41586-023-05802-5","journal-title":"Nature"},{"issue":"7907","key":"1223_CR61","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41586-022-04575-7","volume":"604","author":"X. Barros-\u00c1lvarez","year":"2022","unstructured":"X. Barros-\u00c1lvarez, R.M. Nwokonko, A. Vizurraga, D. Matzov, F. He, M.M. Papasergi-Scott, M.J. Robertson, O. Panova, E.H. Yardeni, A.B. Seven, F.E. Kwarcinski, H. Su, M.C. Peroto, J.G. Meyerowitz, M. Shalev-Benami, G.G. Tall, G. Skiniotis, The tethered peptide activation mechanism of adhesion GPCRs. Nature 604(7907), 757\u2013762 (2022). https:\/\/doi.org\/10.1038\/s41586-022-04575-7","journal-title":"Nature"},{"key":"1223_CR62","doi-asserted-by":"publisher","unstructured":"T. Su, Q. Guan, H. Cheng, Z. Zhu, C. Jiang, P. Guo, Y. Tai, H. Sun, M. Wang, W. Wei, Q. Wang, Functions of G protein-coupled receptor 56 in health and disease. Acta Physiologica 236(2), e13866 (2022). https:\/\/doi.org\/10.1111\/apha.13866","DOI":"10.1111\/apha.13866"},{"key":"1223_CR63","doi-asserted-by":"publisher","unstructured":"H. Chen, X. Hu, W. Ouyang, D. Wang, Y. Wang, Y. Yu, H. Yao, 170P clinical significance and functional role of GPR56 (ADGRG1) in breast cancer. Ann Oncol. 34, S249 (2023). https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2894","DOI":"10.1016\/j.annonc.2023.09.2894"},{"issue":"3","key":"1223_CR64","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/ijms21031100","volume":"21","author":"A. Nowicki","year":"2020","unstructured":"A. Nowicki, P. Skupin-Mrugalska, M. Jozkowiak, M. Wierzchowski, M. Rucinski, P. Ramlau, V. Krajka-Kuzniak, J. Jodynis-Liebert, H. Piotrowska-Kempisty, The effect of 3\u2032-hydroxy-3, 4, 5, 4\u2032-tetramethoxy -stilbene, the metabolite of the resveratrol analogue DMU-212, on the motility and proliferation of ovarian cancer cells. Int. J. Mol. Sci. 21(3), 1100 (2020). https:\/\/doi.org\/10.3390\/ijms21031100","journal-title":"IJMS"},{"issue":"3","key":"1223_CR65","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/neuonc\/noab181","volume":"24","author":"H. Huang","year":"2022","unstructured":"H. Huang, M. Georganaki, L.L. Conze, B. Lavi\u00f1a, L. van Hooren, K. Vemuri, T. van de Walle, M. Ramachandran, L. Zhang, F. Pont\u00e9n, M. Bergqvist, A. Smits, C. Betsholtz, E. Dejana, P.U. Magnusson, L. He, R. Lugano, A. Dimberg, ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma. Neuro-Oncology 24(3), 398\u2013411 (2022). https:\/\/doi.org\/10.1093\/neuonc\/noab181","journal-title":"Neuro-Oncology"},{"key":"1223_CR66","doi-asserted-by":"publisher","unstructured":"A.-D.P. Vo, S.-K. Kim, M.Y. Yang, A.E. Ondrus, W.A. Goddard, Fully activated structure of the sterol-bound smoothened GPCR-Gi protein complex. Proc. Natl. Acad. Sci. U. S. A. 120(49), e2300919120 (2023). https:\/\/doi.org\/10.1073\/pnas.2300919120","DOI":"10.1073\/pnas.2300919120"},{"issue":"12","key":"1223_CR67","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","volume":"361","author":"D.D.V. Hoff","year":"2009","unstructured":"D.D.V. Hoff, P.M. LoRusso, C.M. Rudin, J.C. Reddy, R.L. Yauch, R. Tibes, G.J. Weiss, M.J. Borad, C.L. Hann, J.R. Brahmer, H.M. Mackey, B.L. Lum, W.C. Darbonne, J.C. Marsters, F.J. de Sauvage, J.A. Low, Inhibition of the Hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361(12), 1164\u20131172 (2009). https:\/\/doi.org\/10.1056\/NEJMoa0905360","journal-title":"N. Engl. J. Med."},{"key":"1223_CR68","doi-asserted-by":"publisher","unstructured":"J.J. Luke, S. Pendyala, A. Di Francesco, S. Kim, L. Dellamary, S. Kc, H. Humphreys, M. De Los Rios, J. Pitman, J. Hood, D.S. Hong, 495TiP a phase II study evaluating the safety and efficacy of ENV-101 (taladegib) in patients with advanced solid tumors harboring PTCH1 loss of function mutations. Ann. Oncol. 33, S768 (2022). https:\/\/doi.org\/10.1016\/j.annonc.2022.07.623","DOI":"10.1016\/j.annonc.2022.07.623"},{"issue":"11","key":"1223_CR69","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1093\/neuonc\/noab087","volume":"23","author":"D. Frappaz","year":"2021","unstructured":"D. Frappaz, M. Barritault, L. Montan\u00e9, F. Laigle-Donadey, O. Chinot, E. Le Rhun, A. Bonneville-Levard, A.F. Hottinger, D. Meyronnet, A.-S. Bidaux, G. Garin, D. P\u00e9rol, MEVITEM\u2014a phase I\/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent\/refractory medulloblastoma with sonic Hedgehog pathway activation. Neuro-Oncology 23(11), 1949\u20131960 (2021). https:\/\/doi.org\/10.1093\/neuonc\/noab087","journal-title":"Neuro-Oncology"},{"issue":"14","key":"1223_CR70","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1074\/jbc.RA119.011273","volume":"295","author":"M. D\u00edaz-Cor\u00e1nguez","year":"2020","unstructured":"M. D\u00edaz-Cor\u00e1nguez, C.-M. Lin, S. Liebner, D.A. Antonetti, Norrin restores blood-retinal barrier properties after vascular endothelial growth factor\u2013induced permeability. J. Biol. Chem. 295(14), 4647\u20134660 (2020). https:\/\/doi.org\/10.1074\/jbc.RA119.011273","journal-title":"J. Biol. Chem."},{"issue":"1","key":"1223_CR71","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-024-01563-4","volume":"17","author":"P. Song","year":"2024","unstructured":"P. Song, Z. Gao, Y. Bao, L. Chen, Y. Huang, Y. Liu, Q. Dong, X. Wei, Wnt\/\u03b2-catenin signaling pathway in carcinogenesis and cancer therapy. J. Hematol. Oncol. 17(1), 46 (2024). https:\/\/doi.org\/10.1186\/s13045-024-01563-4","journal-title":"J. Hematol. Oncol."},{"issue":"28","key":"1223_CR72","doi-asserted-by":"publisher","first-page":"2200750","DOI":"10.1002\/advs.202200750","volume":"9","author":"S. Zheng","year":"2022","unstructured":"S. Zheng, J. Lin, Z. Pang, H. Zhang, Y. Wang, L. Ma, H. Zhang, X. Zhang, M. Chen, X. Zhang, C. Zhao, J. Qi, L. Cao, M. Wang, X. He, R. Sheng, Aberrant cholesterol metabolism and Wnt\/\u03b2-catenin signaling coalesce via Frizzled5 in supporting cancer growth. Adv. Sci. 9(28), 2200750 (2022). https:\/\/doi.org\/10.1002\/advs.202200750","journal-title":"Adv. Sci."},{"issue":"4","key":"1223_CR73","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1042\/ebc20220016","volume":"66","author":"M. Katoh","year":"2022","unstructured":"M. Katoh, M. Katoh, WNT signaling and cancer stemness. Essays Biochem. 66(4), 319\u2013331 (2022). https:\/\/doi.org\/10.1042\/ebc20220016","journal-title":"Essays Biochem."},{"issue":"7720","key":"1223_CR74","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41586-018-0447-x","volume":"560","author":"S. Yang","year":"2018","unstructured":"S. Yang, Y. Wu, T.-H. Xu, P.W. de Waal, Y. He, M. Pu, Y. Chen, Z.J. DeBruine, B. Zhang, S.A. Zaidi, P. Popov, Y. Guo, G.W. Han, Y. Lu, K. Suino-Powell, S. Dong, K.G. Harikumar, L.J. Miller, V. Katritch, H.E. Xu, W. Shui, R.C. Stevens, K. Melcher, S. Zhao, F. Xu, Crystal structure of the frizzled 4 receptor in a ligand-free state. Nature 560(7720), 666\u2013670 (2018). https:\/\/doi.org\/10.1038\/s41586-018-0447-x","journal-title":"Nature"},{"issue":"5","key":"1223_CR75","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1016\/j.apsb.2025.03.025","volume":"15","author":"Z. Dong","year":"2025","unstructured":"Z. Dong, Y. Wang, W. Jin, The neuroscience of cancer: focus on neuropeptidergic systems. Acta Pharm Sin B 15(5), 2323\u20132350 (2025). https:\/\/doi.org\/10.1016\/j.apsb.2025.03.025","journal-title":"Acta Pharm Sin B"},{"key":"1223_CR76","doi-asserted-by":"publisher","first-page":"153601212095262","DOI":"10.1177\/1536012120952623","volume":"19","author":"M.D. Childs","year":"2020","unstructured":"M.D. Childs, L.G. Luyt, A Decade\u2019s progress in the development of molecular imaging agents targeting the growth hormone secretagogue receptor. Mol. Imag. 19, 1536012120952623 (2020). https:\/\/doi.org\/10.1177\/1536012120952623","journal-title":"Mol Imag."},{"issue":"1","key":"1223_CR77","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40364-025-00765-3","volume":"13","author":"A. Lin","year":"2025","unstructured":"A. Lin, Y. Ding, Z. Li, A. Jiang, Z. Liu, H.Z.H. Wong, Q. Cheng, J. Zhang, P. Luo, Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence. Biomark Res. 13(1), 50 (2025). https:\/\/doi.org\/10.1186\/s40364-025-00765-3","journal-title":"Biomark Res"},{"issue":"9","key":"1223_CR78","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/s41419-022-05210-z","volume":"13","author":"X. Wang","year":"2022","unstructured":"X. Wang, Z. Qiu, W. Dong, Z. Yang, J. Wang, H. Xu, T. Sun, Z. Huang, J. Jin, S1PR1 induces metabolic reprogramming of ceramide in vascular endothelial cells, affecting hepatocellular carcinoma angiogenesis and progression. Cell. Death Dis. 13(9), 768 (2022). https:\/\/doi.org\/10.1038\/s41419-022-05210-z","journal-title":"Cell. Death Dis."},{"key":"1223_CR79","doi-asserted-by":"publisher","first-page":"039463202311781","DOI":"10.1177\/03946320231178131","volume":"37","author":"Y. Zhang","year":"2023","unstructured":"Y. Zhang, H. Wang, J. Lu, Q. Lv, B. Yun, Z. Ge, L. Yan, Down-regulation of S1PR2 is correlated with poor prognosis and immune infiltrates in cervical squamous cell carcinoma and endocervical adenocarcinoma. Int. J. Immunopathol. Pharmacol. 37, 03946320231178131 (2023). https:\/\/doi.org\/10.1177\/03946320231178131","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"1","key":"1223_CR80","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrc.2017.96","volume":"18","author":"B. Ogretmen","year":"2018","unstructured":"B. Ogretmen, Sphingolipid metabolism in cancer signalling and therapy. Nat. Rev. Cancer 18(1), 33\u201350 (2018). https:\/\/doi.org\/10.1038\/nrc.2017.96","journal-title":"Nat Rev Cancer"},{"key":"1223_CR81","doi-asserted-by":"publisher","first-page":"216891","DOI":"10.1016\/j.canlet.2024.216891","volume":"591","author":"J.H. Ha","year":"2024","unstructured":"J.H. Ha, R. Radhakrishnan, R. Nadhan, R. Gomathinayagam, M. Jayaraman, M. Yan, S. Kashyap, K.-M. Fung, C. Xu, R. Bhattacharya, P. Mukherjee, C. Isidoro, Y.S. Song, D.N. Dhanasekaran, Deciphering a GPCR-lncrna-miRNA nexus: identification of an aberrant therapeutic target in ovarian cancer. Cancer Lett. 591, 216891 (2024). https:\/\/doi.org\/10.1016\/j.canlet.2024.216891","journal-title":"Cancer Lett."},{"issue":"5\u20136","key":"1223_CR82","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10495-022-01723-2","volume":"27","author":"V.K. Gupta","year":"2022","unstructured":"V.K. Gupta, A. Kumar, Targeting lysophosphatidic acid receptor with Ki16425 impedes T cell lymphoma progression through apoptosis induction, glycolysis inhibition, and activation of antitumor immune response. Apoptosis 27(5\u20136), 382\u2013400 (2022). https:\/\/doi.org\/10.1007\/s10495-022-01723-2","journal-title":"Apoptosis"},{"issue":"1","key":"1223_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15384047.2022.2126250","volume":"23","author":"L.T. Maloney","year":"2022","unstructured":"L.T. Maloney, E. Latour, Y. Chen, D. Rice, A. Grossblatt-Wait, N. Nabavizadeh, C.R. Thomas, K.H. Young, J.M. Walker, J. Holland, A.J. Grossberg, Angiotensin receptor blockade and stereotactic body radiation therapy for early stage lung cancer ARB & SBRT for early stage lung cancer. Cancer Biol. Ther. 23(1), 1\u20138 (2022). https:\/\/doi.org\/10.1080\/15384047.2022.2126250","journal-title":"Cancer Biol Ther."},{"issue":"13","key":"1223_CR84","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/jco.23.01134","volume":"42","author":"I. Arrillaga-Romany","year":"2024","unstructured":"I. Arrillaga-Romany, S.L. Gardner, Y. Odia, D. Aguilera, J.E. Allen, T. Batchelor, N. Butowski, C. Chen, T. Cloughesy, A. Cluster, J. de Groot, K.S. Dixit, J.J. Graber, A.M. Haggiagi, R.A. Harrison, A. Kheradpour, L.B. Kilburn, S.C. Kurz, G. Lu, T.J. MacDonald, M. Mehta, A.S. Melemed, P.L. Nghiemphu, S.C. Ramage, N. Shonka, A. Sumrall, R.S. Tarapore, L. Taylor, Y. Umemura, P.Y. Wen, ONC201 (dordaviprone) in recurrent H3 K27M\u2013mutant diffuse midline glioma. J. Clin. Oncol. 42(13), 1542\u20131552 (2024). https:\/\/doi.org\/10.1200\/jco.23.01134","journal-title":"JCO"},{"key":"1223_CR85","doi-asserted-by":"publisher","first-page":"117428","DOI":"10.1016\/j.biopha.2024.117428","volume":"179","author":"J.-Y. Lee","year":"2024","unstructured":"J.-Y. Lee, S. Park, E.J. Park, H.S. Pagire, S.H. Pagire, B.-W. Choi, M. Park, S. Fang, J.H. Ahn, C.-M. Oh, Inhibition of HTR2B-mediated serotonin signaling in colorectal cancer suppresses tumor growth through ERK signaling. Biomed. Pharmacother. 179, 117428 (2024). https:\/\/doi.org\/10.1016\/j.biopha.2024.117428","journal-title":"Biomed. Pharmacother."},{"key":"1223_CR86","doi-asserted-by":"publisher","unstructured":"L.T. Nordquist, E. Lengyelova, F. Almaguel, B.R. Mancini, H. Song, A.J. Armstrong, A.J. Zurita, M. Anderson, M. Parker, R.M. Miller, A. Iagaru, COMBAT: a study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer. J. Clin. Oncol. 42(4_suppl), TPS247\u2013TPS247 (2024). https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.TPS247","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS247"},{"key":"1223_CR87","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cytogfr.2024.03.004","volume":"77","author":"S. Takkar","year":"2024","unstructured":"S. Takkar, G. Sharma, J.B. Kaushal, K.M. Abdullah, S.K. Batra, J.A. Siddiqui, From orphan to oncogene: the role of GPR35 in cancer and immune modulation. Cytokine Growth Factor Rev. 77, 56\u201366 (2024). https:\/\/doi.org\/10.1016\/j.cytogfr.2024.03.004","journal-title":"Cytokine Growth Factor Rev"},{"issue":"9","key":"1223_CR88","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1038\/s44321-024-00121-2","volume":"16","author":"H.-C. Chen","year":"2024","unstructured":"H.-C. Chen, N. Mueller, K. Stott, C. Kapeni, E. Rivers, C.M. Sauer, F. Beke, S.J. Walsh, N. Ashman, L. O\u2019Brien, A. Rafati Fard, A. Ghodsinia, C. Li, F. Joud, O. Giger, I. Zlobec, I. Olan, S.J. Aitken, M. Hoare, R. Mair, E. Serrao, J.D. Brenton, A. Garcia-Gimenez, S.E. Richardson, B. Huntly, D.R. Spring, M.-O. Skjoedt, K. Skj\u00f8dt, M. de la Roche, M. de la Roche, Novel immunotherapeutics against LGR5 to target multiple cancer types. EMBO Mol. Med. 16(9), 2233\u20132261 (2024). https:\/\/doi.org\/10.1038\/s44321-024-00121-2","journal-title":"EMBO Mol Med."},{"key":"1223_CR89","doi-asserted-by":"publisher","first-page":"120596","DOI":"10.1016\/j.lfs.2022.120596","volume":"301","author":"A. Calvillo-Robledo","year":"2022","unstructured":"A. Calvillo-Robledo, R.D. Cervantes-Villagrana, P. Morales, B.A. Marichal-Cancino, The oncogenic lysophosphatidylinositol (LPI)\/GPR55 signaling. Life Sci. 301, 120596 (2022). https:\/\/doi.org\/10.1016\/j.lfs.2022.120596","journal-title":"Life Sci."},{"issue":"16_suppl","key":"1223_CR90","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"C.D. Schinke","year":"2023","unstructured":"C.D. Schinke, C. Touzeau, M.C. Minnema, N.W.C.J. van de Donk, P. Rodr\u00edguez-Otero, M.-V. Mateos, L. Rasche, J.C. Ye, D. Vishwamitra, X. Ma, X. Qin, M. Campagna, T.J. Masterson, B. Hilder, J.A. Tolbert, T. Renaud, J. Goldberg, C. Heuck, A. Chari, Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). J. Clin. Oncol. 41(16_suppl), 8036\u20138036 (2023). https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8036","journal-title":"JCO"},{"issue":"23","key":"1223_CR91","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","volume":"366","author":"A. Sekulic","year":"2012","unstructured":"A. Sekulic, M.R. Migden, A.E. Oro, L. Dirix, K.D. Lewis, J.D. Hainsworth, J.A. Solomon, S. Yoo, S.T. Arron, P.A. Friedlander, E. Marmur, C.M. Rudin, A.L.S. Chang, J.A. Low, H.M. Mackey, R.L. Yauch, R.A. Graham, J.C. Reddy, A. Hauschild, Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 366(23), 2171\u20132179 (2012). https:\/\/doi.org\/10.1056\/NEJMoa1113713","journal-title":"N. Engl. J. Med."},{"key":"1223_CR92","doi-asserted-by":"publisher","unstructured":"A. Villani, G. Fabbrocini, C. Costa, M. Scalvenzi, Sonidegib efficacy and tolerability in advanced basal cell carcinoma: a single-center real-life experience. J. Am. Acad. Dermatol. 86(4), e175 (2022). https:\/\/doi.org\/10.1016\/j.jaad.2021.11.041","DOI":"10.1016\/j.jaad.2021.11.041"},{"issue":"20","key":"1223_CR93","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1158\/1078-0432.Ccr-19-0365","volume":"25","author":"K.J. Norsworthy","year":"2019","unstructured":"K.J. Norsworthy, K. By, S. Subramaniam, L. Zhuang, P.L. Del Valle, D. Przepiorka, Y.-L. Shen, C.M. Sheth, C. Liu, R. Leong, K.B. Goldberg, A.T. Farrell, R. Pazdur, FDA approval summary: glasdegib for newly diagnosed acute myeloid leukemia. Clin. Cancer Res. 25(20), 6021\u20136025 (2019). https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-0365","journal-title":"Clin. Cancer Res."},{"issue":"15_suppl","key":"1223_CR94","doi-asserted-by":"publisher","first-page":"7526","DOI":"10.1200\/JCO.2020.38.15_suppl.7526","volume":"38","author":"A.M. Zeidan","year":"2020","unstructured":"A.M. Zeidan, M. Schuster, M. Joris, J. Krauter, J. Maertens, E. Gyan, T. Kovacsovics, A. Verma, P. Vyas, E.S. Wang, W. Ma, M. Zeremski, A. Kudla, G. Chan, M.A. Sekeres, Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): effects on marrow recovery and transfusion independence. J. Clin. Oncol. 38(15_suppl), 7526\u20137526 (2020). https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.7526","journal-title":"JCO"},{"issue":"1","key":"1223_CR95","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccell.2021.11.007","volume":"40","author":"S. Chen","year":"2022","unstructured":"S. Chen, A.D. Luster, Antihistamines for cancer immunotherapy: more than just treating allergies. Cancer Cell. 40(1), 9\u201311 (2022). https:\/\/doi.org\/10.1016\/j.ccell.2021.11.007","journal-title":"Cancer Cell."},{"issue":"3","key":"1223_CR96","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1245\/s10434-024-16195-8","volume":"32","author":"C. Komine","year":"2025","unstructured":"C. Komine, M. Sohda, T. Yokobori, I. Shioi, N. Ozawa, Y. Shibasaki, N. Nakazawa, K. Osone, T. Shiraishi, T. Okada, A. Sano, M. Sakai, H. Ogawa, K. Kaira, K. Shirabe, H. Saeki, Impact of tumoral \u03b22-adrenergic receptor expression on chemotherapeutic response and prognosis in patients with advanced colorectal cancer. Ann Surg Oncol. 32(3), 1913\u20131924 (2025). https:\/\/doi.org\/10.1245\/s10434-024-16195-8","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"1223_CR97","doi-asserted-by":"publisher","first-page":"100774","DOI":"10.1016\/j.xinn.2024.100774","volume":"6","author":"Z. Bi","year":"2025","unstructured":"Z. Bi, H. Li, Y. Liang, D. Sun, S. Liu, W. Chen, L. Leng, C. Song, S. Zhang, Z. Cong, S. Chen, Emerging paradigms for target discovery of traditional medicines: a genome-wide pan-GPCR perspective. Innovation 6(3), 100774 (2025). https:\/\/doi.org\/10.1016\/j.xinn.2024.100774","journal-title":"Innov"},{"issue":"6","key":"1223_CR98","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41573-020-0062-z","volume":"19","author":"A.P. Davenport","year":"2020","unstructured":"A.P. Davenport, C.C.G. Scully, C. de Graaf, A.J.H. Brown, J.J. Maguire, Advances in therapeutic peptides targeting G protein-coupled receptors. Nat. Rev. Drug. Discov. 19(6), 389\u2013413 (2020). https:\/\/doi.org\/10.1038\/s41573-020-0062-z","journal-title":"Nat Rev Drug. Discov."},{"key":"1223_CR99","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ctrv.2023.102560","volume":"117","author":"A. La Salvia","year":"2023","unstructured":"A. La Salvia, R. Modica, R.E. Rossi, F. Spada, M. Rinzivillo, F. Panzuto, A. Faggiano, S. Cinieri, N. Fazio, Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from NET specialists. Cancer Treat. Rev. 117, 117 (2023). https:\/\/doi.org\/10.1016\/j.ctrv.2023.102560","journal-title":"Cancer Treat. Rev."},{"key":"1223_CR100","doi-asserted-by":"publisher","unstructured":"S.L. Samson, U. Feldt-Rasmussen, S.-L. Zhang, Y. Yu, P. Witek, P. Kalra, M. Bolanowski, Managing high blood sugar (hyperglycemia) during pasireotide treatment: a plain language summary of the B2219 study. Future Rare Dis. 4(1), FRD62 (2024). https:\/\/doi.org\/10.2217\/frd-2023-0025","DOI":"10.2217\/frd-2023-0025"},{"issue":"1","key":"1223_CR101","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/14656566.2016.1258058","volume":"18","author":"M.R. Hoda","year":"2017","unstructured":"M.R. Hoda, W. Kramer, S. Merseburger, M.V. Cronauer, Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer. Expert Opin. Pharmacother. 18(1), 105\u2013113 (2017). https:\/\/doi.org\/10.1080\/14656566.2016.1258058","journal-title":"Expert Opin Pharmacother."},{"issue":"9","key":"1223_CR102","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1016\/j.apsb.2023.03.024","volume":"13","author":"C. Li","year":"2023","unstructured":"C. Li, J. Lang, Y. Wang, Z. Cheng, M. Zu, F. Li, J. Sun, Y. Deng, T. Ji, G. Nie, Y. Zhao, Self-assembly of CXCR4 antagonist peptide\u2013docetaxel conjugates for breast tumor multi-organ metastasis inhibition. Acta Pharm. Sin. B 13(9), 3849\u20133861 (2023). https:\/\/doi.org\/10.1016\/j.apsb.2023.03.024","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"1223_CR103","doi-asserted-by":"publisher","first-page":"2103812","DOI":"10.1002\/advs.202103812","volume":"9","author":"T. Zheng","year":"2022","unstructured":"T. Zheng, W. Wang, M. Mohammadniaei, J. Ashley, M. Zhang, N. Zhou, J. Shen, Y. Sun, Anti-MicroRNA-21 oligonucleotide loaded spermine-modified acetalated dextran nanoparticles for B1 receptor-targeted gene therapy and antiangiogenesis therapy. Adv. Sci. 9(5), 2103812 (2022). https:\/\/doi.org\/10.1002\/advs.202103812","journal-title":"Adv. Sci."},{"issue":"11","key":"1223_CR104","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nrd.2017.91","volume":"16","author":"C.J. Hutchings","year":"2017","unstructured":"C.J. Hutchings, M. Koglin, W.C. Olson, F.H. Marshall, Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat. Rev. Drug. Discov. 16(11), 787\u2013810 (2017). https:\/\/doi.org\/10.1038\/nrd.2017.91","journal-title":"Nat Rev Drug. Discov."},{"issue":"4","key":"1223_CR105","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/17460441.2023.2193389","volume":"18","author":"S.M. Peterson","year":"2023","unstructured":"S.M. Peterson, C.J. Hutchings, C.F. Hu, M. Mathur, J.W. Salameh, F. Axelrod, A.K. Sato, Discovery and design of G protein-coupled receptor targeting antibodies. Expert Opin. Drug. Discov. 18(4), 417\u2013428 (2023). https:\/\/doi.org\/10.1080\/17460441.2023.2193389","journal-title":"Expert Opin Drug. Discov."},{"key":"1223_CR106","doi-asserted-by":"publisher","first-page":"216191","DOI":"10.1016\/j.canlet.2023.216191","volume":"564","author":"P. High","year":"2023","unstructured":"P. High, K.S. Carmon, G protein-coupled receptor-targeting antibody-drug conjugates: current status and future directions. Cancer Lett. 564, 216191 (2023). https:\/\/doi.org\/10.1016\/j.canlet.2023.216191","journal-title":"Cancer Lett."},{"issue":"1","key":"1223_CR107","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1038\/s41467-024-49000-x","volume":"15","author":"R.R. Schlimgen","year":"2024","unstructured":"R.R. Schlimgen, F.C. Peterson, R. Heukers, M.J. Smit, J.D. McCorvy, B.F. Volkman, Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies. Nat. Commun. 15(1), 4611 (2024). https:\/\/doi.org\/10.1038\/s41467-024-49000-x","journal-title":"Nat Commun."},{"issue":"4","key":"1223_CR108","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1124\/molpharm.124.000974","volume":"106","author":"D. Salom","year":"2024","unstructured":"D. Salom, A. Wu, C.C. Liu, K. Palczewski, The impact of nanobodies on G protein\u2013coupled receptor structural biology and their potential as therapeutic agents. Mol. Pharmacol. 106(4), 155\u2013163 (2024). https:\/\/doi.org\/10.1124\/molpharm.124.000974","journal-title":"Mol. Pharmacol."},{"issue":"12","key":"1223_CR109","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1021\/acs.jcim.1c00826","volume":"61","author":"Y. Chen","year":"2021","unstructured":"Y. Chen, O. Fleetwood, S. P\u00e9rez-Conesa, L. Delemotte, Allosteric Effect of nanobody binding on ligand-specific active states of the \u03b22 adrenergic receptor. J. Chem. Inf. Model. 61(12), 6024\u20136037 (2021). https:\/\/doi.org\/10.1021\/acs.jcim.1c00826","journal-title":"J Chem Inf Model."},{"issue":"1","key":"1223_CR110","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41467-021-22810-z","volume":"12","author":"X. Shi","year":"2021","unstructured":"X. Shi, Y. Wan, N. Wang, J. Xiang, T. Wang, X. Yang, J. Wang, X. Dong, L. Dong, L. Yan, Y. Li, L. Liu, S. Hou, Z. Zhong, I.A. Wilson, B. Yang, G. Yang, R.A. Lerner, Selection of a picomolar antibody that targets CXCR2-mediated neutrophil activation and alleviates EAE symptoms. Nat. Commun. 12(1), 2547 (2021). https:\/\/doi.org\/10.1038\/s41467-021-22810-z","journal-title":"Nat Commun."},{"issue":"8","key":"1223_CR111","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41416-023-02192-3","volume":"128","author":"J. Jacob","year":"2023","unstructured":"J. Jacob, L.E. Francisco, T. Chatterjee, Z. Liang, S. Subramanian, Q.J. Liu, J.H. Rowe, K.S. Carmon, An antibody\u2013drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer. Br. J. Cancer 128(8), 1592\u20131602 (2023). https:\/\/doi.org\/10.1038\/s41416-023-02192-3","journal-title":"Br. J. Cancer"},{"issue":"9","key":"1223_CR112","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","volume":"19","author":"Y.H. Kim","year":"2018","unstructured":"Y.H. Kim, M. Bagot, L. Pinter-Brown, A.H. Rook, P. Porcu, S.M. Horwitz, S. Whittaker, Y. Tokura, M. Vermeer, P.L. Zinzani, L. Sokol, S. Morris, E.J. Kim, P.L. Ortiz-Romero, H. Eradat, J. Scarisbrick, A. Tsianakas, C. Elmets, S. Dalle, D.C. Fisher, A. Halwani, B. Poligone, J. Greer, M.T. Fierro, A. Khot, A.J. Moskowitz, A. Musiek, A. Shustov, B. Pro, L.J. Geskin, K. Dwyer, J. Moriya, M. Leoni, J.S. Humphrey, S. Hudgens, D.O. Grebennik, K. Tobinai, M. Duvic, S. Abhyankar, O. Akilov et al., Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 19(9), 1192\u20131204 (2018). https:\/\/doi.org\/10.1016\/S1470-2045(18)30379-6","journal-title":"The Lancet Oncol."},{"key":"1223_CR113","doi-asserted-by":"publisher","unstructured":"A. Chari, C. Touzeau, C. Schinke, M.C. Minnema, J.G. Berdeja, A. Oriol, N.W.C.J. van de Donk, P. Rodr\u00edguez-Otero, D. Morillo, C. Martinez-Chamorro, M.-V. Mateos, L.J. Costa, J. Caers, L. Rasche, A. Krishnan, J.C. Ye, L. Karlin, B. Lipe, D. Vishwamitra, S. Skerget, R. Verona, X. Ma, X. Qin, H. Ludlage, M. Campagna, T. Masterson, B. Hilder, J. Tolbert, T. Renaud, J.D. Goldberg, C. Kane, C. Heuck, J. San-Miguel, P. Moreau, Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study. Lancet Haematol. 12(4), e269\u2013e281 (2025). https:\/\/doi.org\/10.1016\/S2352-3026(24)00385-5","DOI":"10.1016\/S2352-3026(24)00385-5"},{"issue":"1","key":"1223_CR114","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-020-00863-9","volume":"13","author":"V. Pallar\u00e8s","year":"2020","unstructured":"V. Pallar\u00e8s, U. Unzueta, A. Falg\u00e0s, L. S\u00e1nchez-Garc\u00eda, N. Serna, A. Gallardo, G.A. Morris, L. Alba-Castell\u00f3n, P. \u00c1lamo, J. Sierra, A. Villaverde, E. V\u00e1zquez, I. Casanova, R. Mangues, An auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination. J. Hematol. Oncol. 13(1), 36 (2020). https:\/\/doi.org\/10.1186\/s13045-020-00863-9","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"1223_CR115","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1186\/s12885-022-10165-7","volume":"22","author":"S. Hao","year":"2022","unstructured":"S. Hao, S. Xu, L. Li, Y. Li, M. Zhao, J. Chen, S. Zhu, Y. Xie, H. Jiang, J. Zhu, M. Wu, Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4. BMC Cancer 22(1), 1092 (2022). https:\/\/doi.org\/10.1186\/s12885-022-10165-7","journal-title":"BMC Cancer"},{"issue":"16_suppl","key":"1223_CR116","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1200\/JCO.2024.42.16_suppl.2504","volume":"42","author":"J. Gong","year":"2024","unstructured":"J. Gong, C. Liu, J. Yao, J. Xue, J. Dai, Y. Ji, B. Markman, A. Hiong, X. Yang, R. Zhao, Y. Zheng, Q. Li, J. Wu, M.A. Barve, M.H. Ariyapperuma, G.E. Richardson, X. Qin, C.Y. Qin, L. Shen, Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: results from phase 1\/2 studies. J. Clin. Oncol. 42(16_suppl), 2504\u20132504 (2024). https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2504","journal-title":"JCO"},{"issue":"16_suppl","key":"1223_CR117","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1200\/JCO.2025.43.16_suppl.4010","volume":"43","author":"J. Gong","year":"2025","unstructured":"J. Gong, C. Liu, L. Liu, J. Yao, Y. Mou, J. Dai, Y. Chen, X. Yang, M.H. Ariyapperuma, Y. Zhang, J. Xue, J. Coward, Y. Zhou, Y. Ji, Q. Li, R. Zhao, Z. Zhu, B. Markman, H. Li, L. Shen, Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: results from phase 1\/2 studies. J. Clin. Oncol. 43(16_suppl), 4010\u20134010 (2025). https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4010","journal-title":"JCO"},{"key":"1223_CR118","doi-asserted-by":"publisher","first-page":"108822","DOI":"10.1016\/j.pharmthera.2025.108822","volume":"269","author":"A. Bushi","year":"2025","unstructured":"A. Bushi, Y. Ma, J. Adu-Amankwaah, R. Wang, F. Cui, R. Xiao, J. Zhao, J. Yuan, R. Tan, G protein-coupled estrogen receptor biased signaling in health and disease. Pharmacol. Ther. 269, 108822 (2025). https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108822","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"1223_CR119","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.tcb.2020.06.002","volume":"30","author":"L.M. Wingler","year":"2020","unstructured":"L.M. Wingler, R.J. Lefkowitz, Conformational basis of G protein-coupled receptor signaling versatility. Trends Cell. Biol. 30(9), 736\u2013747 (2020). https:\/\/doi.org\/10.1016\/j.tcb.2020.06.002","journal-title":"Trends Cell. Biol."},{"issue":"10","key":"1223_CR120","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41589-025-01896-2","volume":"21","author":"Y. Zheng","year":"2025","unstructured":"Y. Zheng, D. Jiang, Y. Lu, C. Zhang, S.-M. Huang, H. Lin, D. Zhang, S. Guo, J. Han, J. Chen, Y. He, M. Zhang, Y. Gao, Y. Guo, R. Wei, M. Xia, Y. Qin, Z. Liu, F. Yang, S. Ge, F. Yi, X. Yu, H. Lin, P. Xiao, J.-P. Sun, S. Feng, Development of an allosteric adhesion GPCR nanobody with therapeutic potential. Nat. Chem. Biol. 21(10), 1519\u20131530 (2025). https:\/\/doi.org\/10.1038\/s41589-025-01896-2","journal-title":"Nat Chem Biol"},{"key":"1223_CR121","doi-asserted-by":"publisher","first-page":"108829","DOI":"10.1016\/j.pharmthera.2025.108829","volume":"269","author":"W. Liu","year":"2025","unstructured":"W. Liu, D. Wang, L. Wang, S. Hu, Y. Jiang, Y. Wang, X. Cai, J. Chen, Receptor dimers and biased ligands: novel strategies for targeting G protein-coupled receptors. Pharmacol. Ther. 269, 108829 (2025). https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108829","journal-title":"Pharmacol. Ther."},{"key":"1223_CR122","doi-asserted-by":"publisher","unstructured":"L. Ma, F. Yang, X. Wu, C. Mao, L. Guo, T. Miao, S.-K. Zang, X. Jiang, D.-D. Shen, T. Wei, H. Zhou, Q. Wei, S. Li, Q. Shu, S. Feng, C. Jiang, B. Chu, L. Du, J.-P. Sun, X. Yu, Y. Zhang, P. Zhang, Structural basis and molecular mechanism of biased GPBAR signaling in regulating NSCLC cell growth via YAP activity. Proc. Natl. Acad. Sci. U. S. A. 119(29), e2117054119 (2022). https:\/\/doi.org\/10.1073\/pnas.2117054119","DOI":"10.1073\/pnas.2117054119"},{"issue":"2","key":"1223_CR123","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1158\/0008-5472.Can-20-1662","volume":"81","author":"C. Crudden","year":"2021","unstructured":"C. Crudden, T. Shibano, D. Song, M.P. Dragomir, S. Cismas, J. Serly, D. Nedelcu, E. Fuentes-Mattei, A. Tica, G.A. Calin, A. Girnita, L. Girnita, Inhibition of G protein\u2013coupled receptor kinase 2 promotes unbiased downregulation of IGF1 receptor and restrains malignant cell growth. Cancer Res. 81(2), 501\u2013514 (2021). https:\/\/doi.org\/10.1158\/0008-5472.Can-20-1662","journal-title":"Cancer Res."},{"issue":"2","key":"1223_CR124","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.molpha.2024.100013","volume":"107","author":"V.R. Saca","year":"2025","unstructured":"V.R. Saca, T. Huber, T.P. Sakmar, G protein-coupled receptor\u2013targeted proteolysis-targeting chimeras in cancer therapeutics. Mol. Pharmacol. 107(2), 100013 (2025). https:\/\/doi.org\/10.1016\/j.molpha.2024.100013","journal-title":"Mol. Pharmacol."},{"key":"1223_CR125","doi-asserted-by":"publisher","unstructured":"M.E. Huber, L. Toy, M.F. Schmidt, H. Vogt, J. Budzinski, M.F.J. Wiefhoff, N. Merten, E. Kostenis, D. Weikert, M. Schiedel, A Chemical Biology toolbox targeting the intracellular binding site of CCR9: fluorescent ligands, new drug leads and PROTACs. Angew. Chem. Int. Ed. 61(12), e202116782 (2022). https:\/\/doi.org\/10.1002\/anie.202116782","DOI":"10.1002\/anie.202116782"},{"issue":"14","key":"1223_CR126","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1111\/bph.16079","volume":"181","author":"A.C. Keen","year":"2024","unstructured":"A.C. Keen, M. J\u00f6rg, M.L. Halls, The application of targeted protein degradation technologies to G protein-coupled receptors. Br. J. Pharmacol. 181(14), 2351\u20132358 (2024). https:\/\/doi.org\/10.1111\/bph.16079","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1223_CR127","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/cpt.3678","volume":"118","author":"X. Cheng","year":"2025","unstructured":"X. Cheng, Y. Wang, T. Zhang, Y. Cao, H. Cheng, Y. Du, X. Ge, B. Ren, J. Lu, L. Li, Emergence of small nucleic acids as drugs in precision medicine. Clin. Pharma. Ther. 118(2), 308\u2013323 (2025). https:\/\/doi.org\/10.1002\/cpt.3678","journal-title":"Clin Pharma Ther"},{"key":"1223_CR128","doi-asserted-by":"publisher","first-page":"170036","DOI":"10.1016\/j.cej.2025.170036","volume":"525","author":"Y. Zuo","year":"2025","unstructured":"Y. Zuo, J. Yang, C. Wang, M. Wang, Y. Chen, J. Liu, Y. Fang, H. Chen, C. Sun, X. Zhou, T. Zhang, Y. Deng, A. Lu, C. Zheng, S. Chen, J. Lu, Aptamer-engineered multivalent camptothecin conjugates synergistically orchestrate immunosuppressive microenvironment and DNA damage cascades in colorectal carcinoma. Chem. Eng. J. 525, 170036 (2025). https:\/\/doi.org\/10.1016\/j.cej.2025.170036","journal-title":"Chem. Eng-New. Y. J."},{"issue":"7","key":"1223_CR129","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/10837450.2020.1745232","volume":"25","author":"S. Ceylan","year":"2020","unstructured":"S. Ceylan, F. Bahadori, F. Akbas, Engineering of siRNA loaded PLGA nano-particles for highly efficient silencing of GPR87 gene as a target for pancreatic cancer treatment. Pharm. Dev. Technol. 25(7), 855\u2013864 (2020). https:\/\/doi.org\/10.1080\/10837450.2020.1745232","journal-title":"Pharm Dev Technol."},{"issue":"6","key":"1223_CR130","doi-asserted-by":"publisher","first-page":"2401236","DOI":"10.1002\/smtd.202401236","volume":"9","author":"L. Guo","year":"2025","unstructured":"L. Guo, S. Zhang, X. Du, M. Zhou, H. Gu, Fusing allosteric Ribozymes with CRISPR-Cas12a for efficient diagnostics of small molecule targets. Small Methods 9(6), 2401236 (2025). https:\/\/doi.org\/10.1002\/smtd.202401236","journal-title":"Small Methods"},{"issue":"2","key":"1223_CR131","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/acs.accounts.4c00580","volume":"58","author":"M.G. Rafique","year":"2025","unstructured":"M.G. Rafique, Q. Laurent, M.D. Dore, H.H. Fakih, T. Trinh, F.J. Rizzuto, H.F. Sleiman, Sequence-defined DNA polymers: new tools for DNA nanotechnology and Nucleic acid therapy. Acc. Chem. Res. 58(2), 177\u2013188 (2025). https:\/\/doi.org\/10.1021\/acs.accounts.4c00580","journal-title":"Acc Chem Res"},{"key":"1223_CR132","doi-asserted-by":"publisher","unstructured":"M. Takahashi, R. Amano, M. Ozawa, A. Martinez, K. Akita, Y. Nakamura, Nucleic acid ligands act as a PAM and agonist depending on the intrinsic ligand binding state of P2RY2. Proc. Natl. Acad. Sci. U. S. A. 118(18), e2019497118 (2021). https:\/\/doi.org\/10.1073\/pnas.2019497118","DOI":"10.1073\/pnas.2019497118"},{"issue":"1","key":"1223_CR133","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12943-023-01775-1","volume":"22","author":"L. Hovhannisyan","year":"2023","unstructured":"L. Hovhannisyan, C. Riether, D.M. Aebersold, M. Medov\u00e1, Y. Zimmer, CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks. Mol. Cancer 22(1), 82 (2023). https:\/\/doi.org\/10.1186\/s12943-023-01775-1","journal-title":"Mol Cancer"},{"issue":"4","key":"1223_CR134","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41587-024-02446-2","volume":"43","author":"U. Uslu","year":"2025","unstructured":"U. Uslu, C.H. June, Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat. Biotechnol. 43(4), 506\u2013515 (2025). https:\/\/doi.org\/10.1038\/s41587-024-02446-2","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1223_CR135","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-023-01461-1","volume":"16","author":"J. Xia","year":"2023","unstructured":"J. Xia, Z. Li, K. Xu, Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual meeting. J. Hematol. Oncol. 16(1), 60 (2023). https:\/\/doi.org\/10.1186\/s13045-023-01461-1","journal-title":"J. Hematol. Oncol."},{"key":"1223_CR136","doi-asserted-by":"publisher","unstructured":"J. Xia, Q. Sun, D. Zhou, H. Li, Y. Wang, Y. Qi, J. Cao, Z. Yan, D. Li, H. Cheng, W. Sang, F. Zhu, H. Sun, W. Chen, K. Qi, D. Yan, T. Qiu, T. Hu, W. Gu, J. Qian, F. Xia, N. Qi, C. Jin, Y. Liu, X. Wang, Y. Zhang, S. Peng, Z. Li, A.H. Chang, K. Xu, Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 12(5), e365\u2013e375 (2025, May). https:\/\/doi.org\/10.1016\/s2352-3026(25)00048-1","DOI":"10.1016\/s2352-3026(25)00048-1"},{"key":"1223_CR137","doi-asserted-by":"publisher","unstructured":"D. Zhou, Q. Sun, J. Xia, W. Gu, J. Qian, W. Zhuang, Z. Yan, H. Cheng, W. Chen, F. Zhu, K. Qi, D. Li, W. Sang, L. Zhu, S. Ma, H. Li, H. Zhang, T. Qiu, D. Yan, Y. Zhang, S. Peng, A.H. Chang, K. Xu, Z. Li, Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. Lancet Haematol. 11(10), e751\u2013e760 (2024). https:\/\/doi.org\/10.1016\/S2352-3026(24)00176-5","DOI":"10.1016\/S2352-3026(24)00176-5"},{"issue":"10","key":"1223_CR138","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L. Peng","year":"2024","unstructured":"L. Peng, G. Sferruzza, L. Yang, L. Zhou, S. Chen, CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell. Mol. Immunol. 21(10), 1089\u20131108 (2024). https:\/\/doi.org\/10.1038\/s41423-024-01207-0","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"1223_CR139","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41467-023-44310-y","volume":"15","author":"E. Landoni","year":"2024","unstructured":"E. Landoni, M.G. Woodcock, G. Barragan, G. Casirati, V. Cinella, S. Stucchi, L.M. Flick, T.A. Withers, H. Hudson, G. Casorati, P. Dellabona, P. Genovese, B. Savoldo, L.S. Metelitsa, G. Dotti, IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity. Nat. Commun. 15(1), 89 (2024). https:\/\/doi.org\/10.1038\/s41467-023-44310-y","journal-title":"Nat Commun."},{"issue":"1","key":"1223_CR140","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","volume":"23","author":"N. Li","year":"2024","unstructured":"N. Li, S. Geng, Z.-Z. Dong, Y. Jin, H. Ying, H.-W. Li, L. Shi, A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. Mol. Cancer 23(1), 117 (2024). https:\/\/doi.org\/10.1186\/s12943-024-02032-9","journal-title":"Mol Cancer"},{"key":"1223_CR141","doi-asserted-by":"publisher","unstructured":"L.T. Herrera Luis, S. Andreassen S\u00f8ren, J. Caroli, I. Rodr\u00edguez-Espigares, A. Kermani, G. Keser\u0171, A. Kooistra, G. P\u00e1ndy-Szekeres, D. Gloriam, Gpcrdb in 2025: adding odorant receptors, data mapper, structure similarity search and models of physiological ligand complexes. Nucleic Acids Res. 53(D1), D425\u2013D435 (2025). https:\/\/doi.org\/10.1093\/nar\/gkae1065","DOI":"10.1093\/nar\/gkae1065"},{"issue":"6","key":"1223_CR142","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41573-025-01139-y","volume":"24","author":"J.S. Lorente","year":"2025","unstructured":"J.S. Lorente, A.V. Sokolov, G. Ferguson, H.B. Schi\u00f6th, A.S. Hauser, D.E. Gloriam, GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug. Discov. 24(6), 458\u2013479 (2025). https:\/\/doi.org\/10.1038\/s41573-025-01139-y","journal-title":"Nat Rev Drug. Discov."},{"issue":"8","key":"1223_CR143","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.trecan.2025.04.012","volume":"11","author":"Z. Xia","year":"2025","unstructured":"Z. Xia, O. De Wever, The plasticity of cancer-associated fibroblasts. Trends Cancer 11(8), 770\u2013789 (2025). https:\/\/doi.org\/10.1016\/j.trecan.2025.04.012","journal-title":"Trends Cancer"},{"issue":"4","key":"1223_CR144","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/0008-5472.Can-24-1173","volume":"85","author":"J. Nie","year":"2025","unstructured":"J. Nie, S. Zhang, Y. Guo, C. Liu, J. Shi, H. Wu, R. Na, Y. Liang, S. Yu, F. Quan, K. Liu, M. Li, M. Zhou, Y. Zhao, X. Li, S. Luo, Q. Zhang, G. Wang, Y. Zhang, Y. Yao, Y. Xiao, S. Tai, T. Zheng, Mapping of the T-cell landscape of biliary tract cancer unravels anatomic subtype-specific heterogeneity. Cancer Res. 85(4), 704\u2013722 (2025). https:\/\/doi.org\/10.1158\/0008-5472.Can-24-1173","journal-title":"Cancer Res."},{"issue":"2","key":"1223_CR145","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1136\/gutjnl-2024-332429","volume":"74","author":"Y. Yang","year":"2025","unstructured":"Y. Yang, T. Pei, C. Liu, M. Cao, X. Hu, J. Yuan, F. Chen, B. Guo, Y. Hong, J. Liu, B. Li, X. Li, H. Wang, Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A+myeloid cells to promote liver cancer progression. Gut 74(2), 255\u2013269 (2025). https:\/\/doi.org\/10.1136\/gutjnl-2024-332429","journal-title":"Gut"},{"issue":"391","key":"1223_CR146","doi-asserted-by":"publisher","first-page":"114654","DOI":"10.1016\/j.jconrel.2026.114654","volume":"391","author":"C. Zhang","year":"2026","unstructured":"C. Zhang, Y. Chen, X. Shi, Y. Liu, J. Zhou, L. Leng, T. Zhang, S. Liu, J. Liu, T. Wang, C. Zheng, C. Zhang, Y. Deng, J. Guo, J. Lu, Self-assembled multicomponent prodrugs with GSH\/ROS site-responsiveness enable spatiotemporally controlled release for treating resistant NSCLC. J. Control. Release 391(391), 114654 (2026). https:\/\/doi.org\/10.1016\/j.jconrel.2026.114654","journal-title":"J. Control. Release"},{"issue":"8014","key":"1223_CR147","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/s41586-024-07153-1","volume":"629","author":"M.M. Papasergi-Scott","year":"2024","unstructured":"M.M. Papasergi-Scott, G. P\u00e9rez-Hern\u00e1ndez, H. Batebi, Y. Gao, G. Eskici, A.B. Seven, O. Panova, D. Hilger, M. Casiraghi, F. He, L. Maul, P. Gmeiner, B.K. Kobilka, P.W. Hildebrand, G. Skiniotis, Time-resolved cryo-EM of G-protein activation by a GPCR. Nature 629(8014), 1182\u20131191 (2024). https:\/\/doi.org\/10.1038\/s41586-024-07153-1","journal-title":"Nature"},{"issue":"14","key":"1223_CR148","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1111\/bph.16495","volume":"182","author":"M. Lopez-Balastegui","year":"2025","unstructured":"M. Lopez-Balastegui, T.M. Stepniewski, M.M. Kogut-G\u00fcnthel, A. Di Pizio, M.M. Rosenkilde, J. Mao, J. Selent, Relevance of G protein-coupled receptor (GPCR) dynamics for receptor activation, signalling bias and allosteric modulation. Br. J. Pharmacol. 182(14), 3211\u20133224 (2025). https:\/\/doi.org\/10.1111\/bph.16495","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1223_CR149","doi-asserted-by":"publisher","first-page":"100056","DOI":"10.1016\/j.pharmr.2025.100056","volume":"77","author":"I.C. Russell","year":"2025","unstructured":"I.C. Russell, D. Lee, D. Wootten, P.M. Sexton, F. Bumbak, Cryoelectron microscopy as a tool for illuminating activation mechanisms of human class a orphan G protein-coupled receptors. Pharmacol. Rev. 77(3), 100056 (2025). https:\/\/doi.org\/10.1016\/j.pharmr.2025.100056","journal-title":"Pharmacol. Rev."},{"key":"1223_CR150","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.59717\/j.xinn-drugdisc.2026.100002","volume":"1","author":"J.-M. Lehn","year":"2026","unstructured":"J.-M. Lehn, S. Chen, J. Lu, A.S. Chi Chan, Multidisciplinary convergence drives next-generation drug discovery: a new paradigm! Innov. Drug Discov. 1, 100002 (2026). https:\/\/doi.org\/10.59717\/j.xinn-drugdisc.2026.100002","journal-title":"Innov Drug Discov"},{"key":"1223_CR151","doi-asserted-by":"publisher","unstructured":"Y. Zuo, Y. Pu, J. Liu, H. Chen, Y. Chen, X. Li, Y. Wang, T. Zhang, H. Cheng, J. Liu, Y. Deng, Z. Cong, M. Wang, J. Lu, S. Chen, Engineering selective PI3K\u03b3 inhibitors with antitumor and immunomodulatory potentials. Acta Pharm. Sin. B (2025). https:\/\/doi.org\/10.1016\/j.apsb.2025.11.011","DOI":"10.1016\/j.apsb.2025.11.011"},{"key":"1223_CR152","doi-asserted-by":"publisher","first-page":"108242","DOI":"10.1016\/j.pharmthera.2022.108242","volume":"237","author":"M. Persechino","year":"2022","unstructured":"M. Persechino, J.B. Hedderich, P. Kolb, D. Hilger, Allosteric modulation of GPCRs: from structural insights to in silico drug discovery. Pharmacol. Ther. 237, 108242 (2022). https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108242","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"1223_CR153","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1021\/acs.jcim.9b00699","volume":"60","author":"Y. Li","year":"2020","unstructured":"Y. Li, Y. Sun, Y. Song, D. Dai, Z. Zhao, Q. Zhang, W. Zhong, L.A. Hu, Y. Ma, X. Li, R. Wang, Fragment-based computational method for designing GPCR ligands. J. Chem. Inf. Model. 60(9), 4339\u20134349 (2020). https:\/\/doi.org\/10.1021\/acs.jcim.9b00699","journal-title":"J Chem Inf Model."},{"key":"1223_CR154","doi-asserted-by":"publisher","unstructured":"X. Pan, F. Ye, P. Ning, Y. Yu, Z. Zhang, J. Wang, G. Chen, Z. Wu, C. Qiu, J. Li, B. Chen, L. Zhu, C. Qian, K. Gong, Y. Du, Structures of G-protein coupled receptor HCAR1 in complex with Gi1 protein reveal the mechanistic basis for ligand recognition and agonist selectivity. PLoS Biol. 23(4), e3003126 (2025). https:\/\/doi.org\/10.1371\/journal.pbio.3003126","DOI":"10.1371\/journal.pbio.3003126"},{"issue":"3","key":"1223_CR155","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.molcel.2023.12.020","volume":"84","author":"C. Mao","year":"2024","unstructured":"C. Mao, R.-J. Zhao, Y.-J. Dong, M. Gao, L.-N. Chen, C. Zhang, P. Xiao, J. Guo, J. Qin, D.-D. Shen, S.-Y. Ji, S.-K. Zang, H. Zhang, W.-W. Wang, Q. Shen, J.-P. Sun, Y. Zhang, Conformational transitions and activation of the adhesion receptor CD97. Mol. Cell. 84(3), 570\u2013583.e7 (2024). https:\/\/doi.org\/10.1016\/j.molcel.2023.12.020","journal-title":"Mol. Cell."},{"issue":"9","key":"1223_CR156","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1021\/acs.jmedchem.2c02058","volume":"66","author":"Z. Cheng","year":"2023","unstructured":"Z. Cheng, Y. Wang, Y. Zhang, C. Zhang, M. Wang, W. Wang, J. He, Y. Wang, H. Zhang, Q. Zhang, C. Ding, D. Wu, L. Yang, M. Liu, W. Lu, Discovery of 2H-Indazole-3-carboxamide derivatives as novel potent prostanoid EP4 receptor antagonists for colorectal cancer immunotherapy. J. Med. Chem. 66(9), 6218\u20136238 (2023). https:\/\/doi.org\/10.1021\/acs.jmedchem.2c02058","journal-title":"J Med Chem"},{"issue":"1","key":"1223_CR157","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.1038\/s41467-024-49625-y","volume":"15","author":"P. Yan","year":"2024","unstructured":"P. Yan, X. Lin, L. Wu, L. Xu, F. Li, J. Liu, F. Xu, The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer. Nat. Commun. 15(1), 5255 (2024). https:\/\/doi.org\/10.1038\/s41467-024-49625-y","journal-title":"Nat Commun."},{"issue":"1","key":"1223_CR158","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1038\/s41467-020-19058-4","volume":"11","author":"B. Schuster","year":"2020","unstructured":"B. Schuster, M. Junkin, S.S. Kashaf, I. Romero-Calvo, K. Kirby, J. Matthews, C.R. Weber, A. Rzhetsky, K.P. White, S. Tay, Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat. Commun. 11(1), 5271 (2020). https:\/\/doi.org\/10.1038\/s41467-020-19058-4","journal-title":"Nat Commun."},{"key":"1223_CR159","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.omtn.2023.06.011","volume":"33","author":"C. Ducrot","year":"2023","unstructured":"C. Ducrot, M. Piffoux, Combining independent protein and cellular SELEX with bioinformatic analysis may allow high affinity aptamer hit discovery. Mol. Ther. Nucleic Acids 33, 254\u2013256 (2023). https:\/\/doi.org\/10.1016\/j.omtn.2023.06.011","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"9","key":"1223_CR160","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H. Lee","year":"2023","unstructured":"H. Lee, S. Ahn, R. Maity, N. Leblay, B. Ziccheddu, M. Truger, M. Chojnacka, A. Cirrincione, M. Durante, R. Tilmont, E. Barakat, M. Poorebrahim, S. Sinha, J. McIntyre, A. M.Y. Chan, H. Wilson, S. Kyman, A. Krishnan, O. Landgren, W. Walter, M. Meggendorfer, C. Haferlach, T. Haferlach, H. Einsele, M.K. Kort\u00fcm, S. Knop, J.B. Alberge, A. Rosenwald, J.J. Keats, L. Rasche, F. Maura, P. Neri, N.J. Bahlis, Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat. Med. 29(9), 2295\u20132306 (2023). https:\/\/doi.org\/10.1038\/s41591-023-02491-5","journal-title":"Nat Med."},{"issue":"6","key":"1223_CR161","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jpha.2020.01.001","volume":"10","author":"S. Usman","year":"2020","unstructured":"S. Usman, M. Khawer, S. Rafique, Z. Naz, K. Saleem, The current status of anti-GPCR drugs against different cancers. J. Pharm. Anal. 10(6), 517\u2013521 (2020). https:\/\/doi.org\/10.1016\/j.jpha.2020.01.001","journal-title":"J. Pharm. Anal."},{"issue":"29","key":"1223_CR162","doi-asserted-by":"publisher","first-page":"2501420","DOI":"10.1002\/advs.202501420","volume":"12","author":"Y. Zeng","year":"2025","unstructured":"Y. Zeng, Y. Cao, S. Ren, C. Zhang, J. Liu, K. Liu, Y. Wang, H. Chen, F. Zhou, X. Yang, X. Ge, T. Zhang, T. Wang, Y. He, D. Li, C. Zhang, J. Lu, Responsive ROS-Augmented prodrug hybridization nanoassemblies for Multidimensionally Synergitic treatment of hepatocellular carcinoma in cascade assaults. Adv. Sci. 12(29), 2501420 (2025). https:\/\/doi.org\/10.1002\/advs.202501420","journal-title":"Adv. Sci."},{"key":"1223_CR163","doi-asserted-by":"publisher","unstructured":"J. Lu, J.-M. Lehn, A.S. Chi Chan, S. Chen, The Innovation Drug Discovery: an international journal of drug discovery science. Innov. Drug Discov. 100001 (2026). https:\/\/doi.org\/10.59717\/j.xinn-drugdisc.2026.100001","DOI":"10.59717\/j.xinn-drugdisc.2026.100001"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01223-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01223-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01223-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:42:40Z","timestamp":1783986160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01223-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":163,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1223"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01223-4","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}